WuXi AppTec Partners with PSCI to Enhance Pharmaceutical Supply Chain Responsibility

WuXi AppTec Joins Pharmaceutical Supply Chain Initiative

WuXi AppTec, a global leader in providing R&D and manufacturing services for the pharmaceutical and life sciences sectors, has officially become a Supplier Partner of the Pharmaceutical Supply Chain Initiative (PSCI). This partnership reflects the company's ongoing dedication to promoting responsible business practices and enhancing supply chain resilience.

The PSCI is a notable global non-profit organization focused on fostering responsible supply chains in the pharmaceutical and healthcare industries. Its three primary modes of impact — Audit, Capability, and Projects — guide its mission toward achieving excellence in safety, environmental, and social outcomes within the global pharmaceutical landscape. By joining as a Supplier Partner, WuXi AppTec aligns its efforts with PSCI's vision, thereby reinforcing its commitment to sustainable practices across the supply chain.

Edward Hu, the Vice Chairman of WuXi AppTec and Chairman of the ESG Committee, expressed enthusiasm about this new partnership. He stated, "We are pleased to join the PSCI as a Supplier Partner and reaffirm our commitment to fostering responsible business practices across the global supply chain." He emphasized that adherence to PSCI standards will support WuXi AppTec in helping its customers introduce innovative therapies to patients, ultimately contributing to a healthier and more sustainable future.

As a catalyst for innovation, WuXi AppTec plays a vital role in the pharmaceutical and life sciences industry. The company integrates environmental, social, and governance (ESG) priorities throughout its global operations. In 2024, WuXi AppTec achieved top recognition in SP Global's Corporate Sustainability Assessment within the Global Life Sciences Tools and Services industry. Additionally, the company received a gold medal in EcoVadis' business sustainability rating, reinforcing its commitment to sustainable operational practices.

WuXi AppTec's dedication to sustainability has earned it a place on the Dow Jones Sustainability Indices (DJSI) and an AA MSCI ESG rating for four consecutive years. The company has also been recognized in both the SP Global Sustainability Yearbook and the FTSE4Good Index Series, showcasing its efforts in prioritizing corporate social responsibility.

Further solidifying its commitment to sustainability, WuXi AppTec joined the United Nations Global Compact in 2024 to champion the initiative's ten sustainability principles. In 2023, it participated in the Science Based Targets initiative (SBTi), aimed at reducing carbon emissions in line with climate science.

With operations spanning across Asia, Europe, and North America, WuXi AppTec provides an extensive range of R&D and manufacturing services, empowering the global pharmaceutical and life sciences sectors. Its unique business model encompasses a variety of integrated, end-to-end services, including chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing, and clinical research services.

WuXi AppTec's goal is to improve the productivity of advancing healthcare products while offering cost-effective and efficient solutions for its clients. This integration of services enables over 6,000 customers from more than 30 countries to enhance healthcare outcomes and fulfill the vision that "every drug can be made and every disease can be treated."

In conclusion, WuXi AppTec's partnership with PSCI not only highlights its commitment to responsible operations and sustainability but also positions the company to play a pivotal role in evolving the pharmaceutical supply chain for the betterment of global health outcomes.